Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion .
Genetic Technologies LtdJanuary 21, 2021 GMT
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
Key Highlights
Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data